Etco2 Levels on the End-tidal Concentration of Sevoflurane

NCT ID: NCT05778968

Last Updated: 2024-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-01

Study Completion Date

2024-07-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

he assessment of adequate levels of anaesthesia traditionally relies not only on a patient's movement but also on the hemodynamic response (or both) to a surgical stimulus

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently a derivative of MAC namely, end tidal partial pressure (FET) displayed on the work station as concentration , maybe an alternative useful measure of the anaesthetic effect of an inhaled anaesthetic agent

. Many pharmacological factors have been associated with alterations in MAC and Mac derivatives such as nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and anesthetics.

However, few studies have focused on physiological factors, such as hypercarbia or hypocarbia. A correlation has been found between Paco2 and Etco2 in ventilated patients with healthy lungs. Some authors have suggested that Etco2 could be considered appropriate for estimating Paco2 even in critical patients. Knowledge of the effects of Paco2 on end tidal concentration of sevoflurane among patients undergoing laparoscopic cholecystectomy may help anaesthesiologists titrate sevoflurane carefully and precisely during different mechanical ventilation settings to avoid dose-dependent hypotension, impaired cardiac contractility, and hypothermia caused by excessive anaesthetic depth of sevoflurane.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End-tidal Sevoflurane End-tidal Carbon Dioxide Minimum Alveolar Concentration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low ETCO2

Group Type ACTIVE_COMPARATOR

low etco2

Intervention Type PROCEDURE

Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg

normal ETCO2

Group Type ACTIVE_COMPARATOR

normal etco2

Intervention Type PROCEDURE

Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg

high ETCO2

Group Type ACTIVE_COMPARATOR

high etco2

Intervention Type PROCEDURE

Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

low etco2

Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg

Intervention Type PROCEDURE

normal etco2

Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg

Intervention Type PROCEDURE

high etco2

Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of anaesthesiologist ASA physical status I, II
* admitted for laparoscopic cholecystectomy

Exclusion Criteria

* Refusal of patients.

* Patients with renal or liver dysfunction.
* Patients with chronic pain other than cholelithiasis.
* Cardiac disorders as uncontrolled hypertension, arrhythmia, Ischaemic heart disease, valvular heart disease and pulmonary hypertension.
* Patient with haematological disorder as Sickle cell disease.
* Chest patient as asthma, COPD.
* Combined surgery .
* History of allergy to any of the study drugs.
* Patients with communication problems, cognitive dysfunction, or psychological disorders.
* Patients who received analgesics or sedatives 24 h before a scheduled surgery.
* Alcohol or drug abuse.
Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

tarek abdel hay mostafa

principle investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

thanaa elnomany, MD

Role: STUDY_DIRECTOR

tanta university, faculty of medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

tarek Abdelhay Mostafa

Tanta, El Gharbyia, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MAC of sevoflurane

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.